Even as countries try returning to some semblance of pre-pandemic life, ongoing restrictions are wearing thin a crucial human link in the global supply chain.
The Trump administration plans to pump millions of dollars into producing more medications in the U.S. as the coronavirus pandemic heightens longstanding concerns about the fragility of the global drug supply chain.
The coronavirus pandemic has affected virtually every country in the world, but the ability to combat it with essential medicines varies widely. Low- and middle-income countries (LMICs) are finding it especially tough to access medicines, and ensure the safety and quality of those products that are available.
The coronavirus pandemic is bringing about radical changes in global supply chains. But whether companies can draw on the lessons of the present to handle the challenges of future such events is still in question.
The coronavirus pandemic has made it clear that humans make supply chains vulnerable to failure. Greater reliance on automated solutions will be a given from here on out.
COVID-19 is about to put the global trading system through its most dramatic stress-test since World War II, with supply lines for essential food and medical goods entering a critical phase as the pandemic peaks in the U.S. and Europe.
The latest supply-chain news, analysis, trends and tools for executives in the pharmaceutical and biotech industries. Learn how pharmaceutical and biotech companies and their suppliers around the world are managing the flow of products across all channels of the enterprise. Experts sound off on forecasting and demand planning, supply-chain visibility, logistics outsourcing, inventory optimization, transportation management, warehouse management, supply-chain security, corporate social responsibility and more.
Subscribe to our Daily Newsletter!
Timely, incisive articles delivered directly to your inbox.